A kit for prognostic stratification of neuroblastoma patients consisting of: a. oligonucleotides or primer pairs which are specific for each of the following 42 mRNAs: CAMTA2, EPHA5, EPN2, PLAGL1, PTPRN2, SNAPC1, AHCY, AKR1C1, ARHGEF7, BIRC5, CADM1, CDCA5, CDKN3, CLSTN1, CPSG3, DDC, DPYSL3, ECEL1, EPB41L3, FYN, GNB1, HIVEP2, INPP1, MAP7, MAPT, MCM2, MRPL3, MYCN, NME1, NRCAM, NTRK1, ODC1, PAICS, PMP22, PRKACB, PRKCZ, PTN, SCG2, SLC25A5, TYMS, ULK2 and WSB1; or b. oligonucleotides or primer pairs which are specific for each of the following 59 mRNAs: CAMTA2, EPHA5, EPN2, PLAGL1, PTPRN2, SNAPC1, AHCY, AKR1C1, ARHGEF7, BIRC5, CADM1, CDCA5, CDKN3, CLSTN1, CPSG3, DDC, DPYSL3, ECEL1, EPB41L3, FYN, GNB1, HIVEP2, INPP1, MAP7, MAPT, MCM2, MRPL3, MYCN, NME1, NRCAM, NTRK1, ODC1, PAICS, PMP22, PRKACB, PRKCZ, PTN, SCG2, SLC25A5, TYMS, ULK2, WSB1 CAMTA1, CD44, CHD5, ELAVL4, MAP2K4, MTSS1, NHLH2, PDE4DIP, PIK3R1, PLAT, PRAME, PRDM2, PTPRF, PTPRH, QPCT, SLC6A8 and TNFRSF25; or c. oligonucleotides or primer pairs which are specific for each of the following 12 miRNAs: hsa-mir-345, hsa-mir-320, hsa-mir-485-5p, hsa-mir-542-3p, hsa-mir-192, hsa-mir-25, hsa-mir-15b, hsa-mir-326, hsa-mir-93, hsa-mir-572, hsa-mir-17-5p and hsa-mir-20b; or d. oligonucleotides or primer pairs which are specific for each miRNA of the following 25 miRNAs: hsa-mir-628, hsa-mir-345, hsa-mir-500, hsa-mir-320, hsa-mir-485-5p, hsa-mir-542-3p, hsa-mir-192, hsa-mir-92, hsa-mir-26a, hsa-mir-30c, hsa-mir-190, hsa-mir-204, hsa-mir-488, hsa-mir-125b, hsa-mir-18a *, hsa-mir-20a, hsa-mir-19a, hsa-mir-18a, hsa-mir-25, hsa-mir-15b, hsa-mir-326, hsa-mir-93, hsa-mir-572, hsa-mir-17-5p and hsa-mir-20b; or e. a combination of said oligonucleotides which are specific for each of said 42 mRNAs or 59 mRNAs with said oligonucleotides which are specific for each of said 12 miRNAs or 25 miRNAs. a. oligonucleotides or primer pairs which are specific for each of the following 42 mRNAs: CAMTA2, EPHA5, EPN2, PLAGL1, PTPRN2, SNAPC1, AHCY, AKR1C1, ARHGEF7, BIRC5, CADM1, CDCA5, CDKN3, CLSTN1, CPSG3, DDC, DPYSL3, ECEL1, EPB41L3, FYN, GNB1, HIVEP2, INPP1, MAP7, MAPT, MCM2, MRPL3, MYCN, NME1, NRCAM, NTRK1, ODC1, PAICS, PMP22, PRKACB, PRKCZ, PTN, SCG2, SLC25A5, TYMS, ULK2 and WSB1; or b. oligonucleotides or primer pairs which are specific for each of the following 59 mRNAs: CAMTA2, EPHA5, EPN2, PLAGL1, PTPRN2, SNAPC1, AHCY, AKR1C1, ARHGEF7, BIRC5, CADM1, CDCA5, CDKN3, CLSTN1, CPSG3, DDC, DPYSL3, ECEL1, EPB41L3, FYN, GNB1, HIVEP2, INPP1, MAP7, MAPT, MCM2, MRPL3, MYCN, NME1, NRCAM, NTRK1, ODC1, PAICS, PMP22, PRKACB, PRKCZ, PTN, SCG2, SLC25A5, TYMS, ULK2, WSB1 CAMTA1, CD44, CHD5, ELAVL4, MAP2K4, MTSS1, NHLH2, PDE4DIP, PIK3R1, PLAT, PRAME, PRDM2, PTPRF, PTPRH, QPCT, SLC6A8 and TNFRSF25; or c. oligonucleotides or primer pairs which are specific for each of the following 12 miRNAs: hsa-mir-345, hsa-mir-320, hsa-mir-485-5p, hsa-mir-542-3p, hsa-mir-192, hsa-mir-25, hsa-mir-15b, hsa-mir-326, hsa-mir-93, hsa-mir-572, hsa-mir-17-5p and hsa-mir-20b; or d. oligonucleotides or primer pairs which are specific for each miRNA of the following 25 miRNAs: hsa-mir-628, hsa-mir-345, hsa-mir-500, hsa-mir-320, hsa-mir-485-5p, hsa-mir-542-3p, hsa-mir-192, hsa-mir-92, hsa-mir-26a, hsa-mir-30c, hsa-mir-190, hsa-mir-204, hsa-mir-488, hsa-mir-125b, hsa-mir-18a *, hsa-mir-20a, hsa-mir-19a, hsa-mir-18a, hsa-mir-25, hsa-mir-15b, hsa-mir-326, hsa-mir-93, hsa-mir-572, hsa-mir-17-5p and hsa-mir-20b; or e. a combination of said oligonucleotides which are specific for each of said 42 mRNAs or 59 mRNAs with said oligonucleotides which are specific for each of said 12 miRNAs or 25 miRNAs.